telaprevir (Incivo) Naive
following a full submission:
telaprevir (Incivo®) is accepted for use within NHS Scotland.
Indication under review: in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis) who are treatment-naïve.
In the pivotal phase III randomised study, addition of telaprevir to current standard therapy in treatment-naïve patients with genotype 1 chronic hepatitis C virus, significantly increased the proportion of patients who achieved a sustained virologic response, even in patients treated for a shorter overall duration using response-guided therapy.
|Drug Name:||telaprevir (Incivo) Naive|
|SMC Drug ID:||743/11|
|Indication:||In combination with peginterferon alfa and ribavirin (PR), for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis): who are treatment naive|
|Submission Type:||Full submission|
|Date Advice Published:||12 December 2011|